Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
Jakob LauritsenNicolas SauvéAlexey TryakinDi Maria JiangRobert A HuddartDaniel Y C HengAngelika TerbuchEric WinquistMichal ChovanecMarcus HentrichChristian Daniel FankhauserJonathan ShamashXavier García Del Muro SolansDavid VaughnAxel HeidenreichCora N SternbergChristopher SweeneyAndrea NecchiCarsten BokemeyerMikkel BandakAbolghassem JandariLaurence ColletteSilke GillessenJoerg BeyerGedske DaugaardPublished in: British journal of cancer (2023)
Relapsing CSI GCT patients expect similar survival compared to de novo metastatic patients of the same ICCCCG prognostic group. Intermediate and poor prognosis relapses from initial CSI expose patients to unnecessary toxicity from more intensive treatments.
Keyphrases
- end stage renal disease
- poor prognosis
- ejection fraction
- chronic kidney disease
- squamous cell carcinoma
- small cell lung cancer
- prognostic factors
- emergency department
- peritoneal dialysis
- long non coding rna
- oxidative stress
- acute lymphoblastic leukemia
- metabolic syndrome
- systemic lupus erythematosus
- patient reported outcomes
- patient reported
- free survival
- glycemic control
- weight loss
- adverse drug